Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center

Yi-Jou Tai, Heng-Cheng Hsu, Ying-Cheng Chiang, Yu-Li Chen, Chi-An Chen and Wen-Fang Cheng
Additional contact information
Yi-Jou Tai: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Heng-Cheng Hsu: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Ying-Cheng Chiang: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Yu-Li Chen: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Chi-An Chen: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Wen-Fang Cheng: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan

IJERPH, 2019, vol. 16, issue 14, 1-12

Abstract: Adjuvant treatment in advanced-stage (stages III /IV) endometrial carcinomas in terms of tumor grades has not yet been explored. We retrospectively analyzed 194 patients with advanced-stage endometrioid endometrial carcinoma who received surgery, followed by adjuvant therapy, at National Taiwan University Hospital between January 1, 2000 and August 31, 2017. Adjuvant therapies included radiation (RT), chemotherapy alone (CT), and combined modality treatment (CMT: radiation and chemotherapy). The prognostic factors were determined from multivariate survival analyses using Cox regression models. Progression-free survival (PFS) and overall survival (OS) times were estimated with the Kaplan–Meier method. The median follow-up was 45.5 months (range: 6.2–207.9). In grade 1/2 endometrioid carcinoma, neither adjuvant CT nor CMT could prolong PFS significantly compared to RT (CT: HR 1.59, 95% CI 0.64–3.97; CMT: HR 2.03, 95% CI 0.72–5.74). Notably, maximal cytoreduction independently improved PFS (HR 0.31, 95% CI 0.10–0.90). No particular adjuvant treatment provided an OS advantage over the others for grade 1/2 endometrioid carcinomas. However, for grade 3 endometrioid carcinoma, CMT showed OS benefits (HR 0.15, 95% CI 0.03–0.89) compared to RT and CT. In conclusion, maximal cytoreduction should be the goal in patients with grade 1/2 advanced-stage endometrioid carcinomas. Based on our results, patients with grade 3 endometrioid carcinomas might benefit from adjuvant CMT.

Keywords: endometrial neoplasms; adenocarcinoma; endometrioid; chemotherapy; adjuvant; radiotherapy (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/16/14/2561/pdf (application/pdf)
https://www.mdpi.com/1660-4601/16/14/2561/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:16:y:2019:i:14:p:2561-:d:249406

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().